INTRODUCTION
Cardiac rhabdomyoma (CR) is the most commonly diagnosed tumor found in utero and pediatric age group constituting 45%-80% of all primary cardiac tumors. [1] Generally, rhabdomyomas are multiple, well circumscribed, and noncapsulated, but 10% can occur as single intramural or intra cavitary mass. [2] They often show spontaneous regression and need only close followup. CR producing valvular interference, conduction disturbance, or heart failure needs treatment. However, surgical management carries risk. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder and commonly associated with CR. [3, 4] The majority of patients with tuberous sclerosis have inactivating mutations in either TSC1 (9q34.3) or TSC2 (16p13.3) gene, resulting in constitutive activation of m-TOR (mammalian target of rapamycin), a protein when activated is responsible for abnormal proliferative cellular response and cell activation causing hamartomatous lesions in heart, brain, and kidneys. It has been appreciated that m-TOR inhibitors [5, 6] inhibit this action and decrease the presentation seen in all cases. One case had ectopic ventricular rhythm. Baseline characteristics and clinical response are summarized in Table 1 .
Regression was seen in all the five cases with hemodynamically significant CR. Case 1 developed varicella infection 6 weeks after the commencement of everolimus necessitating stoppage of medication for 4 weeks. In this patient, recurrence of right ventricular outflow tract obstruction (RVOTO) was noted after discontinuation of medication. The tumor size and RVOTO were completely resolved after recommencement of everolimus [ Figure 1 ]. Case 2 had superior vena cava obstruction that regressed after 4 months [ Figure 2 ]. Case 3 had severe left ventricular outflow tract obstruction due to CR. Rapid response was noted in 2 months. Cases 4 and 5 had multiple CR diagnosed antenatally, who presented with heart failure due to compromised right ventricular cavity [ Figure 3 ]. Therefore, everolimus was started in the 1 st week itself. Both the cases showed regression of the CR with improvement in symptoms. However, case 4 had sudden cardiac death at home after 4 months of treatment.
The mean ± SD follow-up of 6.1 ± 5.1 months showed significant reduction of CR in all the five cases. Treatment duration and clinical response of all cases are plotted in graph [ Figure 4 ]. There were no complications related to the drug administration or systemic involvement.
DISCUSSION
CR grows rapidly during fetal and neonatal periods due to maternal hormones and then slowly regress due to the withdrawal of maternal hormones. Hemodynamic compromise causing life-threatening complications are documented in some, during this rapid growth period. [10] The surgical excision carries high risk in symptomatic CR due to young age and anatomical variability involving myocardium. Natural history of CR is encouraging. However, spontaneous regression is not seen in all cases. The index case (case 1) in our small cohort had severe RVOTO with right ventricular dysfunction and tricuspid regurgitation. We felt surgery was high risk and difficult as there were multiple lesions in different locations. Aw et al. reported 11.8 times faster regression of CR treated with everolimus compared to natural regression. [9] Hence, abnormal proliferation. There are few case reports of everolimus usage in CR. [5] [6] [7] [8] [9] We report our experience of everolimus in managing CR.
MATERIALS AND METHODS
It is a single-center prospective study conducted from December 2016 to March 2018 in infants with significant CR. Approval from the Institutional Scientific Committee was obtained for the clinical usage of everolimus. Significant CR is defined as the presence of either clinical symptoms or obstruction to the blood flow demonstrated by transthoracic echocardiogram (TTE). Only infants with either single solitary or multiple rhabdomyomas were included in the study. Informed consent was obtained from parents after detailed discussion about the risks and benefits of the medication. Initial thorough clinical examination, chest X-ray, electrocardiogram (ECG), and TTE were performed. Size of the tumor, number, location, hemodynamic interference, and cardiac function were noted. Baseline liver and renal function tests were done. Everolimus was commenced in all eligible children with significant CR. Dose was started in daily divided dose of 4.5 mg/m 2 /week. Route of administration: The drug was diluted with water and taken into syringe and administered orally without touching mucosa. Parents were explained the dose, dilution, and mode of administration clearly. The first dose was given by the parents under the supervision of a doctor and then daily dose to be administered at the same time.
Follow-up clinical examinations including ECG and TTE were done weekly for 4 weeks and then biweekly to see the response. Size of the CR, gradients at the site of obstruction, and cardiac function were noted on follow-up.
RESULTS
There were six children (male: 5) in the study population. One case was excluded after excisional biopsy (histopathology revealed fibroma) for a nonresponding tumor and concomitant closure of large perimembranous ventricular septal defect. The median age and weight were 5 days (range: 1-90) and 3.2 kg (range: 2.2-4.5), respectively. Antenatal diagnosis of CR was done in three cases. Neonatal respiratory distress was the common Dhulipudi, et al.: Everolimus in cardiac rhabdomyoma everolimus was started in our index case, which showed regression of tumor from day 14 of therapy.
Everolimus is an inhibitor of m-TOR protein which regulates cell proliferation. Its biological half-life is 30 h.
Oral everolimus is absorbed rapidly and reaches peak concentration after 1.3-1.8 h. Steady state is reached within 7 days. It is metabolized mainly through CYP3A4 system (cytochrome P450 3A4). [11] Most common adverse effects are stomatitis, upper respiratory tract infection, pneumonia, and gastroenteritis. In our study, low dose of 4.5 mg/m 2 /week in daily divided doses did not cause any serious adverse effects except in case 1 who developed varicella infection probably signifies the importance of immunosuppression while using everolimus. All cases had shown significant regression in terms of size of CR, gradients, and symptoms. One of our patients (case 4) with multiple large CR producing right ventricular cavity obstruction had sudden cardiac death presumed to be due to tumor effect or arrhythmia. We believe that everolimus should be given to all symptomatic cases of CR. However, close monitoring is needed to see the response and side effects of the drug.
Limitations
This study is a small cohort. Multicentric randomized studies involving large cohort are needed to see the safety and efficacy of everolimus. In this study, natural progression of CRs is not compared with modified natural history with everolimus.
CONCLUSION
Everolimus appears to be safe and effective in hemodynamically significant CRs during infancy. However, close monitoring may be needed during the treatment to see the clinical response and adverse effects of the drug.
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